10,570 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Vontobel Holding Ltd.

Key Points

• Vontobel Holding reduced its Regeneron stake by 31.9%, selling 10,570 shares in the third quarter and retaining 22,599 shares valued at approximately $17.1 million. Institutional investors collectively own 83.31% of REGN.
• Regeneron reported strong quarterly results, with revenue rising 16.7% year over year to $4.29 billion and EPS of $14.29 exceeding the $10.16 consensus estimate. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $845.21.
• REGN traded near $790.74, while insiders reported additional sales under pre-arranged Rule 10b5-1 plans. The company also declared a quarterly dividend of $0.94 per share, representing a 0.5% annualized yield.

Vontobel Holding Ltd. cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 31.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,599 shares of the biopharmaceutical company's stock after selling 10,570 shares during the quarter. Vontobel Holding Ltd.'s holdings in Regeneron Pharmaceuticals were worth $17,136,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $26,000. Western Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at approximately $26,000. Armstrong Advisory Group Inc. raised its holdings in Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 28 shares during the period. Mowery & Schoenfeld Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $29,000. Finally, Trust Co. of Vermont acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $29,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on REGN shares. Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Cantor Fitzgerald increased their price target on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an "overweight" rating in a report on Friday, July 31st. Evercore raised their price objective on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an "outperform" rating in a research note on Friday, July 31st. Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a research note on Thursday, July 9th. Finally, HSBC lifted their price objective on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a "buy" rating in a report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $845.21.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly performance supported the bullish case. Regeneron reported second-quarter revenue of $4.29 billion, up 16.7% year over year and above analyst expectations. Earnings per share of $14.29 also exceeded the $10.16 consensus estimate, reinforcing confidence in the company’s earnings momentum. Regeneron earnings and investment narrative
• Positive Sentiment: Positive 84-week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva indicated a sustained reduction in new heterotopic bone lesions and disease flare-ups, with a generally consistent safety profile. The results could strengthen confidence in the treatment’s commercial opportunity. Regeneron OPTIMA trial results
• Positive Sentiment: UBS upgraded REGN to Buy and raised its price target to $978 from $660, citing greater long-term potential for Dupixent and arguing that the market may be undervaluing the business. UBS Regeneron upgrade
• Positive Sentiment: Libtayo received a positive recommendation from the European Medicines Agency’s CHMP for a dosing regimen that could reduce administration frequency from every three weeks to every six weeks after the first 12 weeks, potentially improving convenience and market appeal. Final EU approval is still required. Libtayo CHMP recommendation
• Negative Sentiment: Insider Andrew Murphy sold 4,147 shares worth approximately $3.2 million. The transaction was made under a pre-arranged Rule 10b5-1 plan, limiting its significance, but it may contribute modestly to near-term caution. Regeneron insider sale filing

Regeneron Pharmaceuticals Trading Down 0.7%

NASDAQ REGN opened at $790.74 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $566.11 and a 12 month high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The company has a market capitalization of $81.41 billion, a price-to-earnings ratio of 19.54, a price-to-earnings-growth ratio of 1.37 and a beta of 0.16. The company's fifty day moving average price is $791.72 and its two-hundred day moving average price is $721.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm's revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period last year, the business earned $12.81 EPS. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 47.93 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 9.29%.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the transaction, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. This trade represents a 8.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares of the company's stock, valued at $36,960,559.10. This trade represents a 7.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.